The inhibition of ovulation by a new and potent progestin: a clinical study. (Abstract only)

Viinikka L; Ylikorkala O; Nummi S; Virkkunen P; Ranta T; Alapiessa U; Vihko R
Acta Endocrinologica. 1975; 80(199):303.

A new synthetic progestin, Org 2969 (13-ethyl-11-methyl-ene-18,19-dinor-17alpha-pregn-4-en-20-yn-17-ol), was administered orally to healthy normally menstruating women on Days 1-20 of the menstrual cycle, in doses of 125 mcg (2 women), 60 mcg (3 women), and 30 mcg (3 women). The plasma concentrations of luteinizing hormone, follicle stimulating hormone, progesterone, and estradiol were analyzed by radioimmunoassay on Days 8- 23. The plasma aspartate amino transferase (S-ASAT), alanine amino transferase (S-ALAT), alkaline phosphatase (S-AFOS), gamma glutamyl transpeptidase (S-gamma-GT) and bilirubin (S-BIL) were measured on Days 8, 15, and 23. All these determinations were performed during the preceding control cycle as well as the treatment cycle. All the control cycles of the women included in the study were ovulatory. The treatment cycles were anovulatory in the groups of daily doses of 125 mcg and 60 mcg of Org 2969. On the basis of the hormone determinations, 1 of the treatment cycles with a 30 mcg dose was ovulatory, while the other 2 were anovulatory. All the values for plasma S-ASAT, S-ALAT, S-AFOS, 2-gamma-GT, and S-BIL were within the normal range both during control and treatment cycles, and no rise during the treatment was seen. The results suggest that this new progestin is biologically very active in inhibiting ovulation in the human, and that no indication of side effects on liver function were observed. (FULL TEXT)

Document Number: 
Add to my documents. Add to My Documents